Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
University of Pittsburgh
Bristol-Myers Squibb
Vedanta Biosciences, Inc.
Incyte Corporation
Bristol-Myers Squibb
Jiangsu Cancer Institute & Hospital
Bristol-Myers Squibb
Fukushima Medical University
Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co. Ltd
Fate Therapeutics
Nektar Therapeutics
Incyte Corporation
AIO-Studien-gGmbH
Osaka University
National Cancer Center, Japan